<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and seventy patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) were treated in Basel, from 1976 to 1992 </plain></SENT>
<SENT sid="1" pm="."><plain>Forty one underwent bone marrow transplantation (BMT) and 129 antilymphocyte globulin (ALG) therapy </plain></SENT>
<SENT sid="2" pm="."><plain>As of January 1, 1993, 99 of the 170 patients are alive (58% +/- 7%) and the probability to be alive at 15 years is 54% +/- 4% </plain></SENT>
<SENT sid="3" pm="."><plain>Until now, 29 patients have developed a clonal complication </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> occurred within the ALG group </plain></SENT>
<SENT sid="5" pm="."><plain>Nine patients developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 16 patients <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) and 4 patients both, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative risk of developing a clonal complication after ALG-therapy is 42% +/- 13% at 15 years; for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> this risk is 26% +/- 8% and for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> 25% +/- 5% </plain></SENT>
<SENT sid="7" pm="."><plain>The development of a clonal disease directly affects long term prognosis </plain></SENT>
<SENT sid="8" pm="."><plain>The survival of the patients with stable disease is 81% +/- 10% and 36% +/- 13% for those with <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> (p = 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>The most important risk factor is the type of treatment </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast to patients treated with ALG, none of the patients treated with BMT developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> (p &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>No other clinical parameter, such as age, sex, etiology of SAA, severity of the disease and splenectomy correlate with an increased risk of developing this complication </plain></SENT>
<SENT sid="12" pm="."><plain>In contrast, morphological parameters at the time of diagnosis, during bone marrow regeneration and at remission are indications in this respect.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>